Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR2 |
Variant | I291_Y308del |
Impact List | deletion |
Protein Effect | unknown |
Gene Variant Descriptions | FGFR2 I291_Y308del results in the deletion of eighteen amino acids in the Fgfr2 protein from amino acids 291 to 308 (UniProt.org). I291_Y308del has been identified in the scientific literature (Cancer Res (2023) 83 (8_Supplement): CT016), but has not been biochemically characterized and therefore, its effect on Fgfr2 protein function is unknown (PubMed, Jul 2024). |
Associated Drug Resistance | |
Category Variants Paths |
FGFR2 mutant FGFR2 exon7 FGFR2 exon 7 del FGFR2 I291_Y308del |
Transcript | NM_000141.5 |
gDNA | chr10:g.121519994_121520047del54 |
cDNA | c.871_924del54 |
Protein | p.I291_Y308del18 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_024447890.2 | chr10:g.121515273_121518688del3416 | c.871_924del3416 | p.Q291_E308del18 | RefSeq | GRCh38/hg38 |
NM_001144919.2 | chr10:g.121515216_121515269del54 | c.871_924del54 | p.A291_I308del18 | RefSeq | GRCh38/hg38 |
NM_022970.3 | chr10:g.121519994_121520047del54 | c.871_924del54 | p.I291_Y308del | RefSeq | GRCh38/hg38 |
NM_001320654.2 | chr10:g.121498560_121500833del2274 | c.871_924del2274 | p.L291_E308del18 | RefSeq | GRCh38/hg38 |
NM_001144914.1 | chr10:g.121515144_121515197del54 | c.871_924del54 | p.T291_K308del18 | RefSeq | GRCh38/hg38 |
XM_017015921.3 | chr10:g.121520051_121520104del54 | c.871_924del54 | p.G291_Q308del18 | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121519994_121520047del54 | c.871_924del54 | p.I291_Y308del18 | RefSeq | GRCh38/hg38 |
XM_006717708.4 | chr10:g.121520051_121520104del54 | c.871_924del54 | p.G291_Q308del18 | RefSeq | GRCh38/hg38 |
NM_000141.4 | chr10:g.121519994_121520047del54 | c.871_924del54 | p.I291_Y308del | RefSeq | GRCh38/hg38 |
NM_001144917.1 | chr10:g.121519994_121520047del54 | c.871_924del54 | p.I291_Y308del | RefSeq | GRCh38/hg38 |
NM_022970.3 | chr10:g.121519994_121520047del54 | c.871_924del54 | p.I291_Y308del | RefSeq | GRCh38/hg38 |
NM_023029.2 | chr10:g.121515213_121515266del54 | c.871_924del54 | p.I291_L308del18 | RefSeq | GRCh38/hg38 |
XM_017015924.3 | chr10:g.121515193_121515246del54 | c.871_924del54 | p.L291_T308del18 | RefSeq | GRCh38/hg38 |
NM_022970.3 | chr10:g.121519994_121520047del54 | c.871_924del54 | p.I291_Y308del | RefSeq | GRCh38/hg38 |
XM_024447889.2 | chr10:g.121515270_121517322del2053 | c.871_924del2053 | p.P291_I308del18 | RefSeq | GRCh38/hg38 |
XM_017015920.3 | chr10:g.121520051_121520104del54 | c.871_924del54 | p.G291_Q308del18 | RefSeq | GRCh38/hg38 |
XM_006717710.5 | chr10:g.121520051_121520104del54 | c.871_924del54 | p.G291_Q308del18 | RefSeq | GRCh38/hg38 |
NM_001144917.2 | chr10:g.121519994_121520047del54 | c.871_924del54 | p.I291_Y308del18 | RefSeq | GRCh38/hg38 |
XM_017015925.3 | chr10:g.121515193_121515246del54 | c.871_924del54 | p.L291_T308del18 | RefSeq | GRCh38/hg38 |
NM_022970.4 | chr10:g.121519994_121520047del54 | c.871_924del54 | p.I291_Y308del18 | RefSeq | GRCh38/hg38 |
XM_024447888.2 | chr10:g.121515273_121518688del3416 | c.871_924del3416 | p.Q291_E308del18 | RefSeq | GRCh38/hg38 |
NM_001144918.2 | chr10:g.121515135_121515188del54 | c.871_924del54 | p.K291_P308del18 | RefSeq | GRCh38/hg38 |
XM_024447891.2 | chr10:g.121515195_121515248del54 | c.871_924del54 | p.F291_T308del18 | RefSeq | GRCh38/hg38 |
NM_000141.5 | chr10:g.121519994_121520047del54 | c.871_924del54 | p.I291_Y308del18 | RefSeq | GRCh38/hg38 |
NM_001144916.2 | chr10:g.121515135_121515188del54 | c.871_924del54 | p.K291_P308del18 | RefSeq | GRCh38/hg38 |
NM_001320658.2 | chr10:g.121519994_121520047del54 | c.871_924del54 | p.I291_Y308del18 | RefSeq | GRCh38/hg38 |
NM_001144915.2 | chr10:g.121515213_121515266del54 | c.871_924del54 | p.I291_L308del18 | RefSeq | GRCh38/hg38 |
NM_001144913.1 | chr10:g.121519994_121520047del54 | c.871_924del54 | p.I291_Y308del | RefSeq | GRCh38/hg38 |
XM_024447887.2 | chr10:g.121515270_121517322del2053 | c.871_924del2053 | p.P291_I308del18 | RefSeq | GRCh38/hg38 |
NM_001320658.1 | chr10:g.121519994_121520047del54 | c.871_924del54 | p.I291_Y308del | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 I291_Y308del | cholangiocarcinoma | predicted - sensitive | Pemigatinib | Case Reports/Case Series | Actionable | In a Phase II trial (FIGHT-207), Pemazyre (pemigatinib) treatment resulted in a partial response with a 42.5% decrease in target lesion and a progression-free survival of 14.8 months in a patient with cholangiocarcinoma harboring FGFR2 I291_Y308del (Cancer Res (2023) 83 (8_Supplement): CT016; NCT03822117). | detail... |